Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase

1 week ago 7

Cory Renauer, The Motley Fool

Wed, April 22, 2026 astatine 10:00 AM CDT 4 min read

According to a filing with the Securities and Exchange Commission dated April 21, 2026, Aaron Wealth Advisors LLC bought 1,098,176 shares of MBX Biosciences (NASDAQ:MBX) during the archetypal quarter. The estimated worth of the commercialized was $37.35 million, based connected the mean closing terms during the quarter. The quarter-end worth of the presumption roseate by $32.66 million, a fig that incorporates some the nett acquisition and changes successful the stock price.

This was a buy; the MBX Biosciences involvement represents 1.98% of Aaron Wealth Advisors LLC’s 13F reportable assets aft the filing.
Top holdings aft the filing:
- NYSEMKT: IEFA: $139.12 cardinal (8.0% of AUM)
- NASDAQ: VONV: $101.89 cardinal (5.9% of AUM)
- NASDAQ: VONG: $94.67 cardinal (5.5% of AUM)
- NASDAQ: NVDA: $84.44 cardinal (4.9% of AUM)
- NYSE: SGOV: $65.17 cardinal (3.8% of AUM)
As of April 20, 2026, MBX Biosciences shares were priced astatine $33.78, up 342.1% implicit the past year, outperforming the S&P 500 by 308.73 percent points connected a price-change basis.

Metric

Value

Price (as of marketplace adjacent April 20, 2026)	$33.78
Market capitalization	$1.61 billion
Net income (TTM)	($86.97 million)
One-year terms change	342.1%

MBX Biosciences develops precision peptide therapies targeting endocrine and metabolic disorders, with a pipeline including MBX 2109 (Phase 2 for chronic hypoparathyroidism), MBX 1416 (Phase 1 for post-bariatric hypoglycemia), and MBX 4291 (preclinical for obesity and related comorbidities).
The institution operates a clinical-stage biopharmaceutical concern model, generating worth done the discovery, development, and imaginable aboriginal commercialization oregon licensing of proprietary cause candidates.
Headquartered successful Carmel, Indiana, MBX Biosciences employs 43 radical and focuses connected addressing unmet aesculapian needs successful orphan and specialty illness markets.

MBX Biosciences is simply a clinical-stage biotechnology institution focused connected advancing caller peptide therapeutics for analyzable endocrine and metabolic conditions. The institution leverages expertise successful precision peptide engineering to code unmet aesculapian needs, with a strategical accent connected differentiated, long-acting therapies. Its pipeline and specialized attack presumption it to vie successful high-value orphan and specialty illness markets.

Aaron Wealth Advisors expanded its MBX Biosciences presumption from 70,000 shares astatine the extremity of 2025 to 1,168,176 shares during the archetypal 4th of 2026. Unfortunately for the fund, the banal has lone gained astir 7% this year.

Read Entire Article